Could antibody shots replace daily HIV pills for kids? new trial begins in botswana
NCT ID NCT06508749
First seen May 13, 2026
Summary
This study in Botswana tests whether giving three powerful antibodies by infusion can help children who started HIV treatment early keep the virus suppressed without taking daily antiretroviral pills. About 41 children aged 2 to 12 will receive the antibodies while stopping their usual medication for a period. The goal is to see if the antibodies alone can control the virus and protect the immune system.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Botswana Harvard Health Partnership CRS (CRS #31833)
RECRUITINGGaborone, Botswana
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Francistown CRS (CRS #31891)
RECRUITINGFrancistown, Botswana
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
three broadly neutralizing antibodies (VRC07-523LS, PGDM1400LS, PGT121.414.LS)
What this could lead to
If it works, this could point toward a way for children with HIV to stop daily antiretroviral therapy and still keep the virus under control using periodic antibody infusions.
What could go wrong
This is an early Phase I/II trial with only 41 children, so results may not apply broadly. The antibodies may not prevent viral rebound, and some children could experience side effects or need to restart daily pills.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.